KZR stock forecast
Our latest prediction for Kezar Life Sciences, Inc.'s stock price was made on the Nov. 13, 2019 when the stock price was at 2.72$.
In the short term (2weeks), KZR's stock price should outperform the market by 4.12%. During that period the price should oscillate between -8.62% and +16.85%.
In the medium term (3months), KZR's stock price should outperform the market by 6.43%. During that period the price should oscillate between -18.57% and +46.91%.Get email alerts
About Kezar Life Sciences, Inc.
Kezar Life Sciences, Inc. is a clinical-stage biotechnology company, which discovers and develops novel small molecule therapeutics to treat autoimmunity and cancer. The firm specializes in the areas of protein degradation and protein secretion to discover & develop novel therapies for the treatment of serious and unmet medical needs. Its product include KZR-616, an immunoproteasome inhibitor, has completed testing in healthy volunteers. The company was founded by John Fowler, Christopher J. Kirk and Jack Taunton on February 20, 2015 and is headquartered in South San Francisco, CA.
At the moment the company doesn't generate any revenue.
On its last earning announcement, the company reported a loss of -1.22$ per share.
The book value per share is 6.25$
Three months stock forecastNov. 13, 2019
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|